Research
In-depth company research, stock analysis, and market opportunities from the Smart Investors Daily research team.
Historical Average: UNH's 5-year average forward P/E is roughly 20.0x [cite: 34]. The current valuation represents a tangible discount to its own historical baseline.
Read moreThe market is aggressively penalizing ACI for three distinct factors: the failed merger hangover, the underfunded union pension liabilities, and the structural pressures on its…
Read moreDisclaimer: This report is provided for informational and educational purposes only and does not constitute financial, investment, legal, or tax advice. The valuation metrics and…
Read moreIn a "higher for longer" interest rate environment, corporate refinancing costs escalate. Companies that issued cheap debt during the zero-interest-rate era of the early 2020s are…
Read moreDisclaimer: This report is for informational and analytical purposes only and does not constitute financial, investment, legal, or medical advice.
Read moreThe sudden shift in timing regarding the EG4 partnership prompted an avalanche of shareholder litigation.
Read more| Metric | argenx (ARGX) | Vertex Pharmaceuticals (VRTX) | | :--- | :--- | :--- | | Market Capitalization | ~$51.0 Billion | ~$129.3 Billion | | Forward P/E Ratio | ~24.4x |…
Read moreFurthermore, ABCL635 demonstrated profound improvements in patient-reported sleep outcomes, improving scores by 9 points on the Patient-Reported Outcomes Measurement Information…
Read moreTable 4: Peer Valuation Benchmarks (Q2 2024).
Read moreThe Amicus transaction required a radical reshaping of BioMarin’s balance sheet. Prior to the acquisition, BioMarin operated with a highly conservative capital structure, carrying…
Read moreDisclaimer: The following equity research report is for informational and educational purposes only and does not constitute professional financial, legal, or investment advice. It…
Read moreCrowdStrike is priced for absolute, unyielding perfection. The stock's valuation reflects a broad market consensus that AI proliferation will force global enterprises into a…
Read moreWhile management deserves credit for securing the refund and effectively utilizing the cash to reduce inventory by 3% (to $2.91 billion) and pass some savings to consumers,…
Read moreIs the stock overpriced? The answer depends entirely on execution risk and forward guidance realization.
Read moreDisclaimer: The following report is for informational purposes only and does not constitute financial, investment, or professional advice. Equity investments carry significant…
Read moreThe open question is whether future argenx trials in other unproven indications will suffer a similar fate, or if this failure is isolated to the unique heterogeneity of Sjögren's.
Read moreTo fund its massive operational scaling, Eli Lilly has strategically expanded its debt profile. As of the second quarter of 2026, the company reported approximately $47.9 billion…
Read moreSynthesis: Even after dropping 65%, ALHC is not inherently "cheap." A 29x forward P/E is still a significant premium compared to the mid-teens multiple (16.4x - 19.5x) of scale…
Read moreTotal debt has now declined for four consecutive fiscal years, shrinking by 17.1% year-over-year in the most recent quarter [cite: 5]. This marks the lowest quarterly total debt…
Read moreImmediately following the stock drop, several prominent shareholder rights law firms, including Levi & Korsinsky, LLP and SueWallSt, announced the commencement of investigations…
Read more
